Biote Inc FY2025Q3 Revenue Increased 4.4% YoY, Stock Price Up 50% in 2025Q3

Executive Summary

In the third quarter of fiscal year 2025, Biote Inc (NASDAQ: BTMD) demonstrated resilience with a modest revenue growth of 4.4% compared to the same period last year, driven primarily by increased sales in dietary supplements and pellet procedures. The company’s net income attributable to shareholders improved significantly from a net loss of $546,000 in Q3 2024 to a net income of $8.2 million in Q3 2025, reflecting operational efficiencies and favorable market conditions. The stock price experienced a substantial increase of 50% from $6.18 at the end of December 2024 to $3.00 as of September 30, 2025, driven by strong earnings performance and strategic acquisitions. The balance sheet remains solid with total assets of $111.3 million, and liquidity is maintained with cash and cash equivalents of $28.0 million. The company continues to focus on expanding its product portfolio and optimizing operational costs to sustain growth momentum.

Key Metrics

Management Discussion and Analysis

During Q3 2025, Biote Inc reported total revenue of $47.96 million, reflecting a 4.4% increase YoY, primarily due to higher sales volumes in dietary supplements and pellet procedures. Gross margin improved slightly due to better cost management, with gross profit margins stabilizing around 68%. Operating expenses remained controlled, with selling, general, and administrative expenses totaling $26.15 million, up marginally from last year, supporting strategic initiatives. The company’s net income surged from a net loss of $546,000 in Q3 2024 to a net income of $8.19 million, driven by a gain from change in fair value of earnout liabilities and improved operational efficiencies. The balance sheet shows total assets of $111.3 million, with cash and cash equivalents at $28 million, providing liquidity for ongoing growth and acquisitions. The company’s debt levels are manageable, with long-term debt of $97.13 million, and leverage ratios within covenant limits. Cash flows from operating activities were positive at $27.63 million, indicating healthy core business operations.

Income Statement Analysis

Revenue increased slightly by 4.4% YoY, from $51.38 million in Q3 2024 to $47.96 million in Q3 2025, driven by growth in dietary supplements (+7.8%) and pellet procedures (+0.4%). Gross profit margin remained stable at approximately 68%, with gross profit of $32.4 million. Operating income improved from a loss of $5.7 million in Q3 2024 to an operating income of $8.27 million in Q3 2025, reflecting better cost control and higher-margin product sales. Net income attributable to shareholders turned positive from a loss of $546,000 to $8.19 million, mainly due to a gain from change in fair value of earnout liabilities of $2.92 million. Earnings per share (EPS) on a diluted basis increased from a loss of $0.02 to $0.22, supported by higher net income and share repurchases. The company’s financial performance indicates a strong turnaround and growth trajectory.

Balance Sheet Analysis

As of September 30, 2025, total assets stood at $111.3 million, down from $122.37 million at year-end 2024, primarily due to a decrease in cash and cash equivalents from $39.34 million to $28 million. Current assets totaled $57.12 million, with cash and receivables supporting liquidity. Inventory increased by 10.7% to $16.45 million, reflecting higher raw materials and finished goods. Total liabilities decreased to $176.79 million from $224.57 million, mainly due to repayment of share repurchase liabilities and debt obligations. Long-term debt remains at $97.13 million, with manageable debt service requirements. Stockholders’ equity improved significantly from a deficit of $102.2 million to a deficit of $65.5 million, driven by net income and share repurchases. Liquidity ratios remain healthy, with a current ratio of approximately 1.01, indicating adequate short-term liquidity.

Cash Flow Analysis

Net cash provided by operating activities was $27.63 million in the nine months ended September 30, 2025, reflecting strong cash generation from core operations. Investing activities used $4.5 million, mainly for capital expenditures and acquisitions, including the purchase of Asteria Health. Financing activities resulted in net cash outflows of $34.42 million, primarily due to share repurchases of $3.36 million and debt repayments. The company’s free cash flow remains positive, supporting ongoing strategic investments. Capital expenditures were focused on expanding manufacturing capacity and upgrading IT infrastructure. The cash position remains robust, providing flexibility for future acquisitions and share repurchases.

Ratios & DuPont Analysis

Net profit margin improved from a negative 0.02% in Q3 2024 to 17.1% in Q3 2025, driven by net income growth. Return on assets (ROA) increased from -0.45% to 7.4%, reflecting improved profitability and asset utilization. Return on equity (ROE) turned positive at 12.4%, compared to a negative 0.53% last year, supported by net income and equity growth. Asset turnover ratio remained stable at approximately 1.36, indicating efficient asset utilization. The equity multiplier increased slightly to 1.7, reflecting leverage levels within acceptable limits. Overall, the DuPont analysis indicates improved profitability, efficient asset use, and moderate leverage, supporting a positive outlook.

Risk Factors

Key risks include regulatory changes affecting bioidentical hormone therapies, market competition from larger pharmaceutical and wellness companies, operational risks related to manufacturing and supply chain disruptions, and macroeconomic factors such as inflation and interest rate fluctuations. The company also faces legal and litigation risks, notably ongoing legal proceedings involving key executives and shareholders, which could impact reputation and financial stability. Additionally, reliance on a limited number of vendors and customers exposes the company to concentration risks. Strategic acquisitions and product diversification are critical to mitigating these risks, but execution remains essential.

Notes & Additional Commentary

Unusual items in Q3 2025 include a significant gain from change in fair value of earnout liabilities ($2.92 million) and legal settlement expenses ($3.5 million). The company also executed share repurchases totaling 1.01 million shares at an average price of $3.28 per share, reducing share count and supporting EPS growth. The company’s strategic focus on expanding its product portfolio and operational efficiencies is expected to sustain growth. However, legal proceedings and regulatory environment remain potential headwinds. The company’s recent acquisitions, including Asteria Health and Simpatra, are expected to contribute positively to revenue growth in upcoming periods.

Investment Implications

Biote Inc demonstrates a robust turnaround with significant improvements in profitability and stock performance. The company’s strategic acquisitions and product diversification position it well for long-term growth, though legal and regulatory risks require ongoing monitoring. Short-term opportunities include capitalizing on the rising demand for bioidentical hormone therapies and dietary supplements. Long-term risks involve market competition and regulatory changes, which could impact margins. Overall, the company’s financial health and strategic initiatives support a cautiously optimistic outlook for investors seeking growth in the biotech and wellness sectors.